Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
$2.87M
Mr. John D. Shulman
24.00
New York, NY
Dec 02, 2020
-0.05
$-6.25
0.93
1.65
-6,229.97%
-0.01
0.22
0.72
1.25
-835.45%
-1,459.20%
Similar stocks (6)
Alimera Sciences, Inc.
ALIM
Lifecore Biomedical, Inc.
LFCR
Cumberland Pharmaceuticals Inc.
CPIX
Agile Therapeutics, Inc.
AGRX
Evoke Pharma, Inc.
EVOK
Guardion Health Sciences, Inc.
GHSI
Similar stocks (6)
Alimera Sciences, Inc.
ALIM
Lifecore Biomedical, Inc.
LFCR
Cumberland Pharmaceuticals Inc.
CPIX
Agile Therapeutics, Inc.
AGRX
Evoke Pharma, Inc.
EVOK
Guardion Health Sciences, Inc.
GHSI